Results of therapy with carvedilol, a β-blocker vasodilator with antioxidant properties, in hypertensive patients

American Journal of Hypertension

Volumn 11, Issue 1 II S, 1998, Pages

  Moser, Marvin ^a,c   Frishman, William ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

blocker; Antioxidant; Atherogenesis; Carvedilol; Hypertension; Infarction survival

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ATHEROGENESIS; CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DOUBLE BLIND PROCEDURE; GLUCOSE METABOLISM; HUMAN; HYPERTENSION; INFARCTION; KIDNEY FUNCTION; LIPID METABOLISM; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL;

ADRENERGIC BETA-ANTAGONISTS; AGING; ANTIOXIDANTS; BLOOD PRESSURE; CARBAZOLES; HUMANS; HYPERTENSION; LABETALOL; PROPANOLAMINES; VASODILATOR AGENTS;

EID: 0031891463     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(97)00424-X     Document Type: Conference Paper

References (37)

1. The fifth report (JNC V). Arch Intern Med. 153:1993;154-183.
2. The sixth report (JNC VI). Arch Intern Med. 157:1997;2413-2446.
3. Hebert PR, Moser M, Mayer J, et al. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med. 153:1993;578-581.
4. Staessen J, Fagard R, et al. Recent studies with nitrendipine, a moderate long acting dihydropyridine, that reduces strokes in elderly subjects primarily with isolated systolic hypertension. Lancet. 350:1997;757-764.
5. Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction an overview of the randomized trials . Prog Cardiovasc Dis. 27:1985;335-371.
6. Eggertsen R, Sivertsson R, Andrén L, et al. Acute and long-term hemodynamic effects of carvedilol, a combined β-adrenoceptor blocking and precapillary vasodilating agent, in hypertensive patients. J Cardiovasc Pharmacol. 10:(suppl 11):1987;S97-S100.
7. Hall S, Prescott RI, Hallman RJ, et al. A comparative study of carvedilol, slow-release nifedipine, and atenolol in the management of essential hypertension. J Cardiovasc Pharmacol. 8:(suppl):1991;S35-S38.
8. Hauf-Zachariou U, Widmann L, Zulsdorf B, et al. A double-blind comparison of the effects of carvedilol and captopril on serum lipid concentrations in patients with mild to moderate essential hypertension and dyslipidaemia. Eur J Clin Pharmacol. 45:1993;95-100.
9. Heber ME, Brigden GS, Caruana MP, et al. Carvedilol for systemic hypertension. Am J Cardiol. 59:1987;400-405.
10. Langdon CG, Baxter GA, Young PH. A multicenter comparison of carvedilol with hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension. J Cardiovasc Pharmacol. 18:(suppl):1991;S51-S56.
11. Moser M. Clinical experience with carvedilol. J Hum Hypertens. 7:(suppl 1):1993;S16-S20.
12. Wendt TH, van der Does R, Schrader R, et al. Acute hemodynamic effects of the vasodilating and β-blocking agent carvedilol in comparison to propranolol. J Cardiovasc Pharmacol. 10:(suppl):1987;S147-S150.
13. Widmann L, van der Does R, Horrmann M, Machwirth M. Safety and antihypertensive efficacy of carvedilol and atenolol alone and in combination with hydrochlorothiazide. Eur J Clin Pharmacol. 38:1990;S143-S146.
14. Lund-Johansen P, Omvik P, Nordrehaug JE, et al. Carvedilol in hypertension effects on hemodynamics and 24-hour blood pressure . J Cardiovasc Pharmacol. 19:(suppl 1):1992;S27-S34.
15. Franz I-W, Agrawal B, Wiewel D, et al. Comparison of the antihypertensive effects of carvedilol and metoprolol on resting and exercise blood pressure. Clin Invest. 70:1992;S53-S57.
16. Lund-Johansen P, Omvik P. Chronic haemodynamic effects of carvedilol in essential hypertension at rest and during exercise. Eur Heart J. 13:1992;281-286.
17. Morgan TO, Snowden R, Butcher L. Effect of carvedilol and metoprolol on blood pressure, blood flow and vascular resistance. J Cardiovasc Pharmacol. 10:(suppl):1987;S124-S129.
18. Takabatake T, Ohta H, Yamamoto Y, et al. Combination therapy with carvedilol and nicardipine in essential hypertension an open study . Drugs. 36:(suppl 6):1988;124-128.
19. 1 in noninsulin-dependent diabetics. Drugs. 36:(suppl 6):1988;136-140.
20. Goto Y, Tamachi H, Fusegawa Y, et al. Effects of carvedilol on serum lipids in patients with essential hypertension. J Cardiovasc Pharmacol. 18:(suppl):1991;S45-S50.
21. Seguchi H, Nakamura H, Aosaki N, et al. Effects of carvedilol on serum lipids in hypertensive and normotensive subjects. Eur J Clin Pharmacol. 38:1990;S139-S142.
22. Albergati F, Paternó E, Venuti RP, et al. Comparison of the effects of carvedilol and nifedipine in patients with essential hypertension and noninsulin-dependent diabetes mellitus. J Cardiovasc Pharmacol. 19:(suppl 1):1992;S86-S89.
23. Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. Ann Intern Med. 126:1997;955-959.
24. Marchi F, Ciriello C. Efficacy of carvedilol in mild to moderate essential hypertension and effects on microalbuminuria a multicenter, randomized, open-label, controlled study versus atenolol . Adv Ther. 12:1995;212-221.
25. Dupont AG, Van der Niepen P, Taeymans Y, et al. Effect of carvedilol on ambulatory blood pressure, renal hemodynamics, and cardiac function in essential hypertension. J Cardiovasc Pharmacol. 10:(suppl 11):1987;S130-S136.
26. Morgan TO, Anderson A, Cripps J, et al. The use of carvedilol in elderly hypertensive patients. Eur J Clin Pharmacol. 38:1990;S129-S133.
27. Ruffolo RR Jr, Boyle DA, Venuti RP, et al. Preclinical and clinical pharmacology of carvedilol. J Hum Hypertens. 7:(suppl 1):1993;S2-S15.
28. Bristow MR, Gilbert EM, Abraham WT, et al. Multicenter Oral Carvedilol Heart Failure Assessment (MOCHA) a six-month dose-response evaluation in class II-IV patients (abst) . Circulation. 92:(suppl 1):1995;I-142.
29. Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits clinical progression in patients with mild heart failure (abst). Circulation. 92:(suppl 1):1995;I-395.
30. Das Gupta P, Broadhurst P, Raftery EB, et al. Value of carvedilol in congestive heart failure secondary to coronary artery disease. Am J Cardiol. 66:1990;1118-1123.
31. Packer M, Colucci WS, Sackner-Bernstein J, et al. Prospective, randomized evaluation of carvedilol on symptoms and exercise tolerance in chronic heart failure results of the PRECISE trial (abst) . Circulation. 92:(suppl 1):1995;I-143.
32. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 334:1996;1349-1355.
33. Yue T-L, McKenna PJ, Lysko PG, et al. Carvedilol, a new antihypertensive, prevents oxidation of human low-density lipoprotein by macrophages and copper. Atherosclerosis. 97:1992;209-216.
34. Yue T-L, Cheng H-Y, Lysko PG, et al. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther. 263:1992;92-98.
35. Bril A, Slivjak M, DiMartino MJ, et al. Cardioprotective effects of carvedilol, a novel β-adrenoceptor antagonist with vasodilating properties, in anaesthetized minipigs comparison with propranolol . Cardiovasc Res. 26:1992;518-525.
36. ®) reduces infarct size in a canine model of acute myocardial infarction. Pharmacology. 43:1991;113-120.
37. Sung C-P, Arleth AJ, Ohlstein EH. Carvedilol inhibits vascular smooth muscle cell proliferation. J Cardiovasc Pharmacol. 21:1993;221-227.